{"analyses":[{"ciLowerLimit":"1.34","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.16","estimateComment":"Reference level = Hormone Therapy + Radiation Therapy","groupDescription":"Gray's test was used to compare cumulative incidence between treatment arms (1-sided significance level of 0.025) and the Fine-Gray model was used to calculate hazard ratios.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"2.06","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"3.8","value":"2.7"},{"groupId":"OG001","lowerLimit":"4.4","upperLimit":"7.7","value":"6.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"987"},{"groupId":"OG001","value":"992"}],"units":"Participants"}],"description":"Second biochemical relapse is as defined as follows (after initiation of salvage hormone therapy): A rise in PSA on at least two consecutive cases above the nadir (after initiation of salvage hormone therapy), with the rises in PSA exceeding 1 ng/ml above the nadir; or failure to reach 4 ng/L or less at 18 months. The rates of second biochemical relapse were estimated by means of cumulative incidence functions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.","id":"OG000","title":"Hormone Therapy + Radiation Therapy"},{"description":"Radiation therapy alone","id":"OG001","title":"Radiation Therapy Alone"}],"paramType":"NUMBER","populationDescription":"All eligible patients.","reportingStatus":"POSTED","timeFrame":"From registration to 10 years","title":"Second Biochemical Relapse Rate (10 Years)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}